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Abstract
Recently it was discovered that a transient activation of transcription factor NF-κB can give cells 
properties essential for invasiveness and cancer initiating potential. In contrast, most oncogenes to 
date were characterized on the basis of mutations or by their constitutive overexpression. Study of 
NF-κB actually leads to a far more dynamic perspective on cancer: tumors caused by diverse 
oncogenes apparently evolve into cancer after loss of feedback regulation for NF-κB. This event 
alters the cellular phenotype and the expression of hormonal mediators, modifying signals 
between diverse cell types in a tissue. The result is a disruption of stem cell hierarchy in the tissue, 
and pervasive changes in the microenvironment and immune response to the malignant cells.
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1. Introduction
The role of transcription factor Nuclear Factor kappa B (“NF-κB”) in cell physiology has 
been reviewed extensively, and excellent articles describe mutations on genes that encode 
for NF-κB regulators in lymphoid malignancy [1]. Such mutations are relatively rare in solid 
tumors [2]. Lineages that give rise to solid tumors normally restrict their growth to generate 
solid tissue – this restriction can be overcome by NF-κB in carcinogenesis [3]. However, in 
recent years, study models for adenocarcinoma show oncogenes acting through NF-κB to 
cause cancer [1,4,5]. We selected a few of these models to present key changes in cell 
signaling to highlight the common theme. Lastly, we use leukemia as a model for metabolic 
homeostasis. Cell lineages giving rise to leukemia differ from adenocarcinoma in that they 
possess a natural capacity to initiate rapid clonal growth and migration.
NF-κB is a dimer of proteins with Rel homology domain at the N-terminus (e.g. RelA/p65, 
RelB, NF-κB1/p50, NF-κB2/p52), which forms a complex the Ikappa B protein (IκB) that 
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restricts NF-κB from entering the nucleus (Table 1). IκB can be inducibly or constitutively 
degraded, depending on the signaling context [1]. In many cell types a dimer of RelA with 
p50 regulates NF-κB target genes, including other Rel domain proteins. We focus on RelA 
as a paradigm for NF-κB effects in study systems discussed here unless otherwise specified.
NF-κB activation can proceed through the canonical pathway, or the noncanonical pathway 
[6]. In canonical signaling, IκB protein restricts the Rel dimer. The protein kinase complex 
IKK, which interacts with a variety of proteins (Supporting Table S1) can phosphorylate 
IκB; after phosphorylation, the proteasome degrades IκB [7,8], enabling a rapid nuclear 
entry of Rel proteins, where, depending upon their posttranslational modifications, they 
activate or repress specific groups of target genes [9]. “Noncanonical” signaling takes place 
when the restricting protein is p100. p100 processing gives rise to the protein p52, which 
forms a dimer with RelB [6]. During cell stress, other proteins, such as tumor suppressor 
p53, can restrict RelA from entering the mitochondria [10]. Multiple proteins thereby ensure 
a tight regulation of NF-κB activity. Under conditions of high expression of the RelA 
protein, or mutations of enzymes that modify RelA function, some cell types escape 
feedback regulation of NF-κB activity, as we discuss in section 5.2. We focus on proteins 
that show why feedback control of NF-κB activity is critical in shaping the 
microenvironment in malignancy, including cell phenotypes, immune response, and material 
exchange within a niche.
2. NF-κB subunit RelA is modified to control multiple signal transduction 
pathways
NF-κB regulates cell differentiation and its inflammatory responses [1]. What makes NF-κB 
unique is the fact that it is activated in response to diverse changes in the host tissue, and has 
the capacity to alter the state of the host tissue and of multiple components of the immune 
system profoundly. Signals that modulate RelA (Fig. 1A) activity affect stability, tertiary 
structure, and specific combination of charged and hydrophobic residues exposed on RelA, 
and determine: 1. whether RelA associates specifically with nuclear, mitochondrial, or 
cytoplasmic proteins; 2. the gene promoters or enhancers RelA associates, modulating 
transcriptional activity.
RelA interacts with a number of key regulatory proteins, such as nuclear hormone receptors, 
either by direct physical association, or through competition for coactivators and 
corepressors [11]. In this way steroid hormones and inflammatory cytokines regulate one 
another. Several growth factors, or cytokines, binding to their transmembrane receptors, as 
well as cell stress, elicit intracellular signal cascades that activate distinct Rel proteins, 
depending on the cell type [12,13]. Recipient cells, in turn, respond by integrating those 
signals and expressing adhesion molecules, enzymes, and mediators that coordinate cellular 
function within their microenvironment [13,14].
Metabolism and oxidant stress can impact RelA transcriptional activity [12,14]. As an 
example, in human pancreatic ductal adenocarcinoma cells, abnormally high enzymatic 
activities of the hexosamine biosynthetic pathway modify RelA and upstream kinases IKKα 
and IKKβ; inducing RelA phosphorylation on serine 536, nuclear translocation, NF-κB 
Vlahopoulos et al. Page 2
Cytokine Growth Factor Rev. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
transcriptional activity, target gene expression, and thereby facilitating anchorage-
independent growth [15].
In contrast RelA can also turn into an activator of apoptosis, by phosphorylation on 
Threonine 505, which can be induced by cisplatin in susceptible cells [16]. Depending, 
therefore, on the cellular assortment of proteins that interact with RelA, its activation can 
either kill or reprogram the cell. In contrast to non-malignant cells, where regulation of the 
activity of Rel-modifying enzymes makes cell survival depend on tissue integrity, in a 
cancer cell enzymes that modify RelA operate according to mechanisms overriding tissue-
imposed control (Fig 1B). This uncouples cell survival from tissue integrity and normal 
function (Fig 1C).
It is very important to note that RelA controls expression of genes encoding several of 
its’own regulators, including the inhibitor IκBα and activating kinases IKKα and IKKβ [17] 
As these kinases interact with diverse signal mediators (Supplementary Table S1), many 
effects of transiently induced RelA on regulation of cell physiology may escape attention. In 
contrast, it is already known that synthesis of non-canonical pathway proteins RelB and p52, 
is controlled by canonical signaling [18]. Hence, aberrant function of the canonical pathway 
can have indirect effects on cellular function downstream of the non-canonical pathway, 
with a severe impact on tissue integrity.
3. Interactions between diverse cell types shape tissue function through 
NF-κB
RelA on one hand mediates the expression of many inflammatory genes, and on the other it 
can activate survival genes in both normal and cancer cells [19]. A central theme in RelA 
activity is that it opposes growth restrictions on the cell [20], and prepares the cell for 
developmental change.
Almost any type of cell stress or inflammatory mediator can induce NF-κB activity [14]. 
Infection, injury, or toxic organ damage, can cause cell death: reactive oxygen species 
(ROS), and varied sources of genotoxic and metabolic stress can be elevated above the 
threshold that a cell tolerates [21]. Under cytotoxic conditions, certain cell types are needed 
for survival of the organism. In this case NF-κB, by increasing expression of several cohorts 
of metabolic enzymes and key hormones, can balance stress signals, and thereby protects 
essential cells [11,14,22,23]. NF-κB target genes consequently include cytokines, adhesion 
molecules, and specialized functional units of immune cells, as well as antiapoptotic 
proteins like Bcl-2 and Bfl-1, [13,24-26]. Cytokines and adhesion molecules mediate 
communication between an individual cell and its surrounding tissue, as well as the rest of 
the organism. Which are their effects on tissue?
Inflammation lasts from the phase of initiation to the phase of resolution, with restoration of 
normal function [27]. It activates changes in numerous cell types in the microenvironment: 
complementary groups of leukocytes, epithelial, mesenchymal, and endothelial cells interact 
through adhesion molecules and cytokines, to sequentially activate the processes of immune 
cell recruitment, extravasation (passing through blood vessel walls into tissues), tissue 
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infiltration, ROS release, induction of antioxidant systems, cell reprogramming and 
transdifferentiation, matrix component deposition, and immune system suppression (Fig. 
2A) [28-30]. Therefore, to protect host tissue, activity of NF-κB is tightly regulated:
a) Certain cell types that function in immune response need to persist as long as the 
response lasts. For example, innate immune response will ideally last for a 
restricted time in order to protect the host tissue [31]. The lymphocytes that 
facilitate adaptive immunity, however, need to live on and retain essential 
properties: they undergo lasting changes in their chromosomes. NF-κB target 
genes like Bfl-1 help such cells survive, essentially protecting cells with 
genomic rearrangements - a property shared with cancer cells [13,32].
b) Cells necessary to fill in developing or damaged tissues, are either formed by 
mesenchymal cells, adult tissue stem cells, or by reversal of differentiation of 
cells that form local tissue [33]. Cytokines can increase the pool of available cell 
precursors, both through differentiation of stem cells [34], and by 
reprogramming of tissue resident cells [35]. Other cells, instead of forming 
replacement units, are induced to supply essential molecules to the stem cells, 
forming “feeder” niches [36,37].
Through these processes NF-κB -dependent genes coordinate interaction between tissues, 
with drastic effects on cell function. This cross-talk is disrupted in cancer (Fig 1C): in a 
normal cell, enzymes that mediate activation of NF-κB are regulated according to the role of 
the cell in development and inflammation by inducing signal pathways that lead to 
resolution of the initial trigger [27]. In contrast, in tumor cells, under certain conditions, NF-
κB mediates propagation of cell clones that have lost a key feedback inhibiting mechanism 
(Fig 2B); the result is cancer [14,15,38]. Malignant cells may respond to a lethal stimulus 
through a signal pathway that is disproportionately activated (Fig 1B), and has a critical 
influence on downstream enzymes [14,22], as we discuss in section (6).
4. Control of NF-κB impacts cell differentiation
RelA is rather stable and abundant in most cell types [1,10]. Its main natural inhibitor, IκBα, 
on the contrary, is susceptible to proteolysis by proteasome, lysosome, or calpain, and may 
differ greatly between different cell types, different states of growth, and diverse signals 
[7,8]. Within tumors, both proteasome and calpain activity can be increased [39]. As RelA 
activation is downstream of receptor-initiated signals, and subject to amplification cascades, 
its activity can become independent from cell surface receptors (Fig. 3) [1,11].
Interference of RelA with cellular factors linked to differentiation is critical for its role in 
epithelial neoplasia. Components of mechanisms that guide differentiation and migration of 
epithelial lineage cells are disrupted in neoplastic development of many solid tumors 
[33,34]. Estrogen-regulated pathways via the estrogen receptor (ER) are often involved in 
breast cancer, and androgen via the androgen receptor (AR) in prostate cancer [11,40]. RelA 
plays an interesting role in each of these processes: it may enhance ER or AR - mediated 
signal pathways that activate cell growth and proliferation, while inhibiting potently the ER- 
or AR- mediated signals that lead to cell differentiation [11,23].
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Additionally, embryonal stem cells regulate STAT3 (signal transducer and activator of 
transcription 3), Nanog, and noncanonical NF-κB signaling in balance with canonical 
signaling to maintain pluripotency [18, 41-43], which implies that loss of control for 
canonical signaling in neoplasia could give rise to a subpopulation of malignant cells with 
properties overlapping stem cells.
In innate immune system cells, including microglial cells of the central nervous system, 
RelA nuclear translocation is inducible (as in most mammalian cells), and leads to 
inflammation; because IκBα gene expression is induced by RelA, innate immune responses 
are normally self-limiting (reversible [29,35]).
Cells that mediate adaptive immunity tend to increase basal levels of NF-κB activity. 
Rapidly induced RelA activates c-Rel gene expression, facilitating survival of activated B- 
and T-lymphocytes [13], while cells that function in memory storage for the immune 
system, maintain a balanced level of Rel activity [1,13,44]. Similarly, during dendritic cell 
maturation, rapidly activated dimers (e.g., p50/RelA) bound to a subset of target promoters 
are gradually replaced by slowly activated dimers (e.g., p52/RelB); this prolongs expression 
of specific NF-κB target subsets in dendritic cells [45]. Consequently, regulation of cytokine 
expression by dendritic cells, reflected in the proportions between secreted cytokines IL10, 
IL23, and IL-12, depends on the cell maturation stage [46]. Tumors that express 
cyclooxygenase (COX)-2, and secrete its’ product prostaglandin E2, inhibit RelB activity in 
dendritic cells; result is increased IL-10, decreased IL-12 expression, and impaired antigen 
presentation by the dendritic cells [47]. At the molecular level dendritic cell maturation and 
function in antitumor immunity, including T-cell priming, are impaired by induction of the 
transcription factor STAT3 [48].
In the organism, however, the ability to limit RelA activity is important to prevent chronic 
inflammation and myeloid malignancy: knockout of the miR-146a gene (a Rel target and 
feedback regulator) in C57BL/6 mice, led to increased transcription of NF-κB-regulated 
genes, and development of myeloid malignancies with high content of nuclear RelA. This is 
an example of loss of feedback control on RelA [49].
5. Constitutive NF-κB activity and feedback changes affect cancer
In diverse types of cancer, constitutive NF-κB activity enables a malignant cell to survive 
oncogene activation, tumor suppressors, radiation, drug treatments, extensive genetic 
alterations and the surveillance of both innate and adaptive immune cells [19,50,51]. As an 
example of biochemical challenge, oxidant stress can impact several distinct stages of NF-
κB dependent signals, inducing different subsets of genes in different cell types. Depending 
on the cellular assortment of coregulators, NF-κB can mediate either positive or negative 
feedback to oxidant stress causing the propagation or termination of inflammatory cascades 
[29]. The cell exposed to oxidant stress may survive or die, depending on the 
posttranslational modifications of Rel proteins and the rest of the cellular proteome that 
interacts with them, resulting in the expression of different sets of target genes [9,19]. The 
gene products themselves interact with the cell's genome and proteome, and thereby 
modulate further: gene expression, DNA repair, cell cycle control, mitochondrial function, 
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vesicle transport and contents, oxidant-neutralizing enzymes, salvage metabolism, and 
competition with surrounding cells for nutrients and tissue space. Consequently, the ability 
of the organism to kill this cell by inducing biochemical stress is diminished (Figs 2B, 3B).
In a tissue, through disrupted regulation of NF-κB activity and ensuing cytokine expression, 
tumors may perpetuate inflammation by concomitant expression of factors that in normal 
cells are expressed inducibly [24], and by blending features that belong to cells of different 
types [52,53], and different stages of maturation (Fig. 3B) [1,12,54]. Increased levels of 
inflammatory mediators that activate cell movement across tissues facilitate cancer cell 
passage through organs, and ultimately, metastasis [39,55].
5.1. Sequential expression of inflammatory mediators is altered in cancer
The function of NF-κB -dependent hormonal mediators in orchestrating interaction between 
innate and adaptive immunity with host tissue is pivotal in cancer development. Through 
these mediators cancer cells shape their microenvironment, which is shown by their effects 
on cell differentiation and phenotypic adjustments, changes in material turnover, and cross-
talk with a range of immune cell types. We limit discussion of this subject on the 
interactions between a few selected feedback regulators of NF-κB that control key aspects of 
its' impact on host tissue, which provides the targets for design of subtype-specific 
intervention strategies. As we discuss in detail below, loss of NF-κB control in malignant 
cells changes expression of inflammatory mediators. Result is that signals for tissue 
regeneration can coexist with propagation of inflammation, even though in a normal tissue, 
regeneration signals suppress inflammation. This affects multiple cell types and is essential 
feature of cancer. In particular, characterization of protein families of transcription factors 
NF-κB, AP-1 (activating protein-1) and STAT3, which have gene targets that include 
inflammatory mediators, adhesion molecules and antiapoptotic proteins [24,50,55] provided 
a molecular basis for the role of inflammation in cancer. Many inflammatory mediators 
influence transendothelial migration of inflammatory cells and vascular permeability. Their 
presence in cancer, however, is not ubiquitous.
Notably, the fact that cancer can remain undetected for years until disease has progressed 
[56], means that it can develop without overt inflammation [26]. Disease progression, in 
contrast, is often marked by systemic increase of inflammatory cytokines [24]. And 
furthermore, an inflammatory response may also lead to resolution of the tumor: for 
example, experimental NF-κB hyperactivation in tumor tissues, by combined stimulation 
with IFNα with poly-I:C (a TLR3 ligand) can allow reprogramming of the chemokine 
microenvironment to enhance the recruitment of cytolytic T effector cells [57]. When 
applied individually each chemokine modulator generated a heterogeneous response for 
different tumors, while the response was uniform for the combination of IFNα and poly-I:C, 
and was enhanced by inhibitors of prostaglandin E2 production [57]. The clinical 
significance of the proportions between secreted products of NF-κB target genes can be 
appraised by the discovery that the ratio of inflammation-inducing to inflammation resolving 
cytokines can be reverse between a) pathological conditions involving overt inflammation 
[25] and b) cancer [58].
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As is often evident by the display of different sets of markers by a single fraction of a 
specific malignant tumor [59], the cancer cell can become a mosaic of gene expression 
patterns and phenotypic markers that are normally encountered in cells from different tissues 
and different developmental stages (stem cells, precursor cells, and mature, differentiated 
cells) [33], [55], [60], [61], [62]. Somatic tumors do not originate from a single source or 
developmental phase. For example, different stages of B-cell maturation can give rise to 
lymphomas, and NF-κB is involved in many cases [1]. Mantle cell lymphoma is an 
aggressive malignancy supported by aberrant B cell receptor (BCR) signaling, which is 
targeted by inhibitors ibrutinib and sotrastaurin. While either drug can inhibit BCR-induced 
canonical NF-κB signaling, in many cases malignant B-cells can survive through the 
alternative NF-κB pathway [63]. Oncogenesis does not follow a strict pattern of signal relay, 
and is not confined to a single cell source, even if gene expression follows certain lineage-
dependent restrictions. However, analysis of gene expression gives information on the NF-
κB target gene signature that is essential to identify critical downstream pharmacological 
therapeutic targets [64]. When combined with the study of cultured cells, genetic analysis 
enables a personalized approach to tumors unforeseen by standard therapeutic protocols 
[65]. Apart from personalized treatment, a clinical approach for mantle cell lymphoma, is to 
interfere with malignant cell metabolism by inhibiting mammalian target of rapamycin 
(mTOR) threonine kinase, which is a target of IKKβ and acts in synergy with NF-κB [66],
[67].
A large number of genes that are activated by NF-κB and associated with oncogenesis and 
chronic inflammation contain STAT3 DNA-binding sites. In contrast, many genes 
associated with antitumor immunity lack STAT3 DNA-binding sites and can only be 
activated by NF-κB when STAT3 is inhibited in tumors [68]. STAT3 facilitates NF-κB 
binding to genes that are important for tumor growth while inhibiting its binding to Th-1 (T-
helper cell type 1) stimulatory genes in growing tumors, including tumor-infiltrating 
immune cells (Fig. 3B). The result is that the tumor cell is not attacked by the immune 
system. In contrast, in normal T-cells STAT3 limits NF-κB activation, IL-2 production, and 
proliferation [69].
The change of NF-κB targets brought about by STAT3 in a malignant cell [68], allows the 
cell to reach high NF-κB activity in its nucleus, by overcoming negative feedback 
mechanisms (such as IκBα activation by NF-κB) [1]. Tumor cells that exhibit this type of 
constitutive NF-κB/STAT3 activity become competitive for niche occupation, and can 
induce cells from adjacent tissues to secrete biomolecules and metabolites, and possibly to 
undergo autophagy [19,36,37]. The resulting secreted products aid malignant cell 
propagation, specifically favoring cells that have neutralized tumor suppressors. STAT3 
physically interacts with NF-κB to activate the catalytic subunit of telomerase (tert) in 
human breast cancer stem cells [70]. What is interesting is that once NF-κB overcomes the 
restraints posed by p53 activity, it is no longer subject to inhibition by glucocorticoid 
receptor (“GR”) [71]. NF-κB then can perturb the homeostatic effects of STAT3, GR, and 
p53 in mitochondria (schematic illustration in Fig. 3) [10,72].
STAT3 and p53, in normal cells limit NF-κB-driven immune responses to protect tissue 
integrity; this task is performed in coordination with GR [71,72]. Malignant cells that have 
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lost the gene that encodes p53, exhibit decreased response to glucocorticoids [71], increased 
expression of NF-κB target genes [10], and increased ratio of incoming/secreted exosomes 
[73]. Similar effects can be expected when genes that mediate control of NF-κB by p53 and 
STAT3 are epigenetically repressed.
Cytokines regulated by transcription factors, NF-κB and STAT3, found to participate in 
cancer-related inflammation include IL-1β, IL-6, IL-23, and TNF-α [14,24] (Fig. 3 B). They 
can facilitate tumor growth through activation of other cytokines such as IL-8, and several 
types of adhesion molecules [12,36] culminating in: 1). 1) induction of expression for 
survival proteins ( Mcl-1, Bcl-2, etc.,) on tumor cells [74], 2) growth arrest, senescence, 
autophagy, secretory phenotype [36], and apoptosis in cohorts of surrounding cells (due to 
the presence of intact p53), 3) proliferation or quiescence in different cohorts of neoplastic 
cells, 4) decrease in the efficiency of immune response against the tumor, and 5) metastasis 
[24]. It is very important to emphasize that through the restrictions on NF-κB activity, an 
organism links tissue function and system homeostasis to the control of cell survival (Figure 
4). As a specific example, abnormally high levels of the cytokine IL-6 can confer multiple 
carcinogenic properties to immortalized cells, as we discuss in the next section.
5.2. NF-κB dysregulation permits oncogenes like myc to cause cancer
Many different types of oncogenes cause cancer that depends on NF-κB; here we address a 
few representative studies of adenocarcinoma models. Inflammatory breast cancer, a 
particularly lethal disease, is characterized by NF-κB activity [75]. In cell culture, transient 
activation of Src oncoprotein (Rous sarcoma virus proto-oncogene tyrosine-protein kinase 
homolog) can mediate an epigenetic switch from immortalized breast cells to a stably 
transformed line that forms self-renewing mammospheres that contain cancer stem cells 
[76]. This switch is possible because Src activates NF-κB, inducing thereby Lin28 
expression, thus decreasing levels of let7 miRNA; the result is activation of the cytokine 
IL-6, which induces STAT3 expression. Result is further increase in NF-κB activity. Normal 
breast epithelial cells express at least one negative regulator of NF-κB activity, namely 
miR-146b, which is a direct STAT3 target gene [77]. However, in cancer cells, in spite of 
high STAT3 activity, miR-146b levels may remain low, especially when the miR-146b gene 
promoter is methylated. Breast cancer patient samples that express IL-6 and show STAT3 
activity correlate with a negative prognosis when miR-146b levels are low [77]. Thereby in 
breast cancer cells, a shift in RelA target genes, caused by transcription factor STAT3, could 
play a role at least in some phases of carcinogenesis. The higher activity of STAT3 in some 
tumors could result from activation of NF-κB by an “above-threshold” event such as 
transient activation of Src [76]. Therefore, a positive feedback loop that works in a tumor - 
such as above-threshold activation of NF-κB or of its inflammatory gene targets (Fig. 3B) - 
may constitute an identifiable drug target. Such a therapeutic intervention may become safer 
when specific tissues or cells are targeted [11].
The NF-κB/STAT3 positive feedback loop noted [76], had an interesting aspect: myc 
mRNA levels increased at a pace that followed stat3 mRNA. Interestingly, in the 
transcription factor chromatin immunoprecipitation results obtained with the ENCODE 
project on the human genome [78], binding sites for STAT3 on the myc gene are 
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particularly dense (Fig. 5A). Analysis of p53 transcriptional function via genome-wide 
chromatin occupancy and gene expression identified STAT3 as antagonist for p53 on the 
myc gene [79]. Inhibition of STAT3 activity can suppress myc expression in cultured cells 
[80]. In conclusion, the NF-κB-STAT3 interaction can affect cell fate by activating 
expression of myc [81]. In human T lymphocytes, for example Protein Kinase C theta-
activated NF-κB signaling regulates the expression of telomerase (tert) via c-Myc, which 
inhibits cellular senescence. More important, is probably the fact that c-Myc activates the 
coordinated expression of genes that modulate cellular metabolism, growth, and 
proliferation; when expressed at high levels, is also capable of mediating resistance to cell 
cycle arrest at the G1 phase by rapamycin [82], or to metabolic effects of AMPK activators 
[83]. By increasing the metabolic and oxidant burden, c-Myc increases cellular dependence 
on the NF-κB functions that decrease growth restrictions:
a) NF-κB competes with p53 both in the nucleus and in mitochondria. Many tumor 
cells have defects either in the tp53 gene itself, or in p53-linked pathways [84], 
or have Serine 536-phosphorylated RelA, which is an effective inhibitor of p53 
activity [85,86]. With Ser-536-phosphorylated RelA, tumors may override IκBα 
and p53-imposed restrictions on metabolism and growth [87]. This enables 
tumors to use a higher glycolytic rate that is consistent with the Warburg effect 
[88], and thereby compete with cells that have wildtype p53.
b) NF-κB activates myc expression, and at the same time, expression of survival 
proteins that can quench apoptotic signals from Myc [21]. In three-dimensional 
cell cultures, incorporation of a cell in its natural niche restricts several 
oncogenes including myc, ccnd1, akt1, from completing cancer cell development 
[89]. This means that oncogenes have increased need for cooperating events 
within a natural niche. Importantly, NF-κB can cooperate with Myc for 
telomerase gene expression [90]. Higher telomerase activity allows a tumor cell 
to gain a “competitive edge” over stromal cells, and utilize them as a feeder 
stromal layer:
Indeed, while human and mouse fibroblasts can become tumorigenic upon lentiviral 
transduction with an SV40 large T antigen (to sequester p53 and Rb tumor suppressors) and 
oncogenic Ras, the naked mole-rat fibroblast proved resistant. This resistance to oncogene-
induced tumorigenesis was reversed by transduction with human telomerase. Naked mole-
rat fibroblasts then formed tumors that grew rapidly in immunodeficient mice [91]. It is 
important to note that they have high constitutive levels of p53 protein [92], which is 
apparently overridden by increased telomerase expression. Therefore disruption of the 
negative feedback between factors such as STAT3 and RelA, can augment the capacity of 
transformed cells for malignant growth by amplifying expression of target genes like myc, 
and thereby fitting subclones of tumor cells with biochemical properties that are essential for 
malignant growth. One of the simplest approaches, therefore, to restore function of tumor 
suppressors in cancer is to inhibit key components of the resulting inflammatory response, 
regardless of whether it is a direct or an indirect consequence of cancer itself [93]. This 
approach is also supported by the fact that drugs such as metformin, as we will discuss next, 
inhibit synergistic NF-κB activity with STAT3 at concentrations that do not kill normal 
cells.
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6. NF-κB effects on tissue: shaping the microenvironment
In spite of enormous genetic heterogeneity between cancers, common themes exist. One of 
them is a higher mutation rate in the later stages [94]; this is consistent with dysregulation of 
the p53 network that normally links cell survival to genetic integrity [95]. As p53 interacts 
with RelA [71] dysregulation of the p53 network leads to the question if RelA targets are 
overexpressed in cancer [96], and which molecular mechanisms mediate their effects on the 
microenvironment [97]. We know that malignant cells secrete signaling molecules such as 
cytokines and metabolites to redirect the phenotype of cells in surrounding tissue [37,98,99]. 
and that diverse types of cancer can secrete signaling molecules that disrupt the immune 
responses [51,68]; interaction between cancer and stroma may allow a tumor escape 
rejection, even after being recognized by adaptive immunity [100]. Carcinoma cells through 
secretion of IL-6, IL-8, CXCL10, and CCL5, (their expression depending on RelA) 
overcome the control of Hypoxia-Induced Factors (HIF) and induce CD11b+Gr-1+ myeloid 
cells to promote tumor growth and angiogenesis [101]. Loss of the control of cytokine 
expression by the NF-κB /p53 interaction network, enables immunosuppression and 
disruption of tissue integrity, in spite of signals for regeneration. Pancreatic adenocarcinoma 
recently emerged as a model for the effects of aberrant NF-κB feedback by its interaction 
partners, especially p53: multiple cytokines and chemokines including IL-6, IL-23, CXCL1, 
CCL20, and CSF3, were expressed by premalignant pancreatic ductal epithelial cells in a 
RelA-dependent manner to promote development of metastatic cancer [102]. Thereby loss 
of feedback restriction on RelA results to aberrant coordination of secretion of the mediators 
for inflammation and regeneration, preventing the restoration of tissue integrity, and the 
physiological function of the immune response (indications exist that this role can be 
generalized in neoplasia: eg., for a variety of pediatric malignancies, IL-6 is a predictor of 
severe infections [103] ). In pancreatic cancer IL6 is known to promote an 
immunosuppressive microenvironment [104]. Systemic inflammation with activity of NF-
κB, IL-6, and STAT3 not only did not clear mice from pancreatic cancer xenografts, but 
instead blocked chemotherapy and gemcitabine from clearing the tumors [105]. In 
confirmation of the role of NF-κB, blocking of gemcitabine-induced RelA nuclear 
translocation, decreases levels of MMP (metalloprotease)-2, MMP-9, VEGF, and IL-8, 
inhibiting angiogenesis and invasion [106].
How could loss of feedback control of NF-κB disrupt the components of the 
microenvironment? Two target molecules that can contribute to this effect are fascin and 
TGFβ.
In most normal or transformed cells, as we have seen, NF-κB has the capacity to interfere 
with transcription factors important in cell phenotype and fate. The main reason for lifting 
phenotypic restrictions for most cells and reversing properties of cellular differentiation is 
that during inflammation the organism needs to concentrate tissue-resident cells on the 
challenge (e.g. infection, or necrotic tissue), and after cessation of the challenge, to prime 
resident cells for terminating the inflammatory response and restoring function. One gene 
essential in cell migration is fascin [107]. In metastatic breast cancer cells, IL6-induced 
STAT3 cooperates with TNF-induced NF-κB to activate fascin expression [108]. In the 
process of normal mammary gland morphogenesis or luminal differentiation, transcription 
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factor GATA3 would limit fascin gene expression [109]. Moreover, glucocorticoids can 
further reduce fascin expression, and thereby allow the formation of tight junctions, which 
are essential for building epithelial barriers [110]. Thus normal tissue function relies on 
negative feedback regulation of inflammatory mediators. This negative feedback regulation 
results in an on-off cycle for NF-κB in normal cells and tissues [111], which is lost in 
adenocarcinoma, as indicated by the effects of deregulated expression of its downstream 
targets that we discuss next.
In adenocarcinoma TGFβ can suppress antigen presentation, cytotoxic T cells, natural killer 
(NK) cells, and induce FoxP3+ regulatory T cells that inhibit the antitumor immune 
response [112,113]. It is very interesting to note the convergence of binding sites for NF-κB, 
STAT3 and c-Myc toward the gene encoding for TGFβ on the human chromosome 19 (Fig 5 
B). TGFβ on the one hand regulates epithelial-mesenchymal transition [114], and on the 
other hand suppresses systemic immunity, hence facilitating metastasis [115]. In fact, 
impaired control of signaling between NF-κB, TGFβ, and HIF1 is implicated in cancer 
metastasis and organ failure [116,117]. Importantly, however, disruption of the NF-κB 
feedback control by TGFβ, demonstrates the potential to compromise tissue regeneration 
and integrity: elevated TGFβ levels in the tumor microenvironment can contribute to fascin 
overexpression [118,119]. It is interesting to note that TGFβ can use NF-κB as a mediator 
for gene expression in epithelial-mesenchymal transition [120], and therefore is a key node 
for positive feedback to NF-κB during cell transformation by oncogene ras. In the presence 
of oncogenic Ras, inflammatory stimuli trigger NF-κB-mediated positive feedback that 
amplifies Ras activity to pathological levels, generating pancreatic adenocarcinoma in mice 
[4].
The same positive feedback is likely to occur also in colon, lung, and other types of 
adenocarcinoma [4]. In a normal cell TGFβ poses certain growth restrictions, however in 
subpopulations of eg. [121], pancreatic cancer cells NF-κB can substitute for TGFβ 
signaling in epithelial-mesenchymal transition [120] and thus increase metastatic tumor 
burden. Furthermore, by inducing overexpression of myc as we discussed in the previous 
chapter, dysregulated NF-κB activity can overcome restrictions on angiogenesis and 
neovascularisation, which are normally imposed by TGFβ [122]. Thereby TGFβ ceases to 
function as a tumor suppressor in the adenocarcinoma cell. Hence on the one hand cancer 
cells can grow unrestricted by the presence of TGFβ, and on the other hand TGFβ still 
affects other cells that are abundant in the tissue. Specifically, TGFβ restricts the antigen-
presenting function of myeloid cells [123], and in parallel, enables myeloid cells to prevent 
CD8(+) T cells from blocking adenocarcinoma metastasis [115]. In adenocarcinoma cells, 
therefore, a loss of negative regulation of NF-κB by TGFβ, allows them to respond 
differently to stimuli that normally induce tumor suppression, and to amplify downstream 
signals, affecting surrounding tissue. Components of the metastatic niche in this way disrupt 
the ordered mobilization of cells involved in inflammation and regeneration, compromising 
the integrity of tissue function and immune response (Figure 4).
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7. Niche effects and material turnover: insight enabled by study of 
lymphoid malignancy
Cells of lymphoid malignancies in, can survive in niches that produce autocrine or paracrine 
factors such as IL-6, which stimulate parts of the stem cell signal transduction apparatus 
[37,124]. IL6 - by activating STAT3 - inhibits cell death from cytotoxic drugs such as 
arsenite [125]. In the hematopoietic stem cell niche myeloma cells compete with normal 
hematopoietic cells for mediators and metabolites supplied by stromal cells [37,124,125].
Resistance of cancer cells to toxic agents and immune responses is augmented by a flow of 
secretory microvesicles and exosomes, resulting in a deterioration of the stroma in favor of 
the tumor. One trigger for this flow are cytokines, such as IL-6 [124]. The flow of 
microvesicles and exosomes between stromal and tumor cells is regulated by NF-κB [36], 
STAT3 [126], and p53 [73]. The exchange of contents between tumor and normal cells can 
therefore have a specific direction (due to partial or total inactivation of p53 networks in the 
former). Secretory vesicles transport a variety of lipids, proteins, and nucleic acids, 
including mRNA, and microRNAs: flow of microvesicles and exosomes results in 
redistribution of regulatory, metabolic and structural components [127]. The result is a 
substantial enhancement of cancer cell resistance to stress, in spite of deregulated material 
turnover [21]. How does homeostasis function in cancer cells? In contrast with carcinoma, 
leukemia originates from cell lineages with inherent capacity for clonal growth and cell 
migration: lower burden of complexity in carcinogenesis makes leukemia a better model for 
resistance of cancer by induction of homeostatic responses, as we see next.
Glucocorticoids kill lymphoblasts causing acute leukemia [128]. High-dose glucocorticoid 
treatment may cause a certain degree of hyperglycemia. During induction therapy, this is 
associated with poorer survival in children with acute lymphocytic leukemia [129]. 
Glycolysis has been identified as one potential pathway of resistance of leukemia cells to 
glucocorticoid [130], and STAT3 has been identified as a stress-responsive transcription 
factor, capable of interacting with glucocorticoid-regulated pathways [131]. High activity of 
STAT3 was observed in lymphoma cells with signatures corresponding to NF-κB activity, 
proliferation, and glycolysis [132]. STAT3 activated by IL-6 can enhance expression of the 
glycolytic enzymes hexokinase 2 and 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase-3 (PFKFB3) [133].
Cultured leukemia cells that were resistant to glucocorticoid treatment [128], could be killed 
by proteasome inhibition, the main signature effect being inhibition of STAT3 target genes 
[21]. At least a portion of glucocorticoid-resistant leukemia, therefore, can be treated by 
drug combinations that include inhibitors of proteasome and modulators of STAT3-
dependent metabolism. Indeed, experimental evidence suggests that leukemia cells do not 
operate a metabolism identical to other components of the immune system, and seem to be 
particularly sensitive to inhibition of STAT3-regulated pathways: the hypoglycemic drug 
metformin, which inhibits STAT3 transcriptional activity in lymphocytes [134], elicits 
autophagy and apoptosis in leukemic cells (IC50 for patient samples ranged between 0.6 and 
0.9mM at 96h), while not having a comparable toxicity on normal proliferating CD4(+) T-
lymphocytes from healthy donors [135].
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Hyperactivation of the STAT3 inducer JAK2 can make malignant cells sensitive to 
metabolic inhibition: 3-hydroxy-3-methyl-glutaryl coenzyme A (HMG-CoA) reductase 
inhibitors - widely used to treat hypercholesterolemia - induce apoptosis and inhibit JAK2-
V617F-dependent neoplastic cell growth. These cells are more sensitive to statin treatment 
than non-JAK2-V617F-dependent cells. Importantly, statin treatment inhibited 
erythropoietin-independent erythroid colony formation of primary cells from 
myeloproliferative neoplasia patients, but had no effect on erythroid colony formation from 
healthy individuals [136]. A hypercholesterolemia that is followed by severe 
hypocholesterolemia, indicates that at least a portion of neoplastic cells utilize cholesterol 
and can be targeted by statin treatment [137].
8. Homeostatic challenges: impact on NF-κB activity in solid and lymphoid 
tumors
Subclones of cancer cells may escape death by activating intracellular protein turnover, 
through exchange of vesicles with stromal cells, and by selective recruitment of groups of 
cells of the immune system. Inflammatory mediators and metabolites also enable diverse 
subpopulations of cancer cells to cooperate or compete, influence their microenvironment, 
and ultimately develop new phenotypes. This lifts key tissue-mediated restrictions on cell 
fate.
The ability of tumor cells to evade chemotherapy, radiation, and targeted therapy is very 
often proportional to their capacity to activate salvage pathways and exploit homeostasis 
mechanisms that are normally heavily restricted in normal cells [14,106, 138-140]. Normal 
undifferentiated cells, for example, are very sensitive to changes in conditions and 
differentiation stimuli [10,34]. Tumor initiating cells, in contrast, may retain stem cell 
properties even after exposure to differentiation stimuli [141]; maintaining homeostasis is a 
challenge. A solution utilized by tumor cells, is to increase proteasome activity [142]. 
Higher activity of the proteasome in healthy cells ensures a good probability of the organism 
living longer, by removing misfolded proteins [143]. Aberrantly high activity of the 
proteasome in tumor cells ensures their selective advantage over healthy cells, and the 
removal of apoptosis inducers [142].
Malignant cells can respond to proteasome inhibition by activating NF-κB and restoring 
mechanisms for their survival by activating salvage pathways, such as lysosome 
acidification [8]. Cascade-initiating mechanisms are redundant in neoplasia under certain 
conditions: under selective pressure exerted by drugs, a malignant cell may ultimately retain 
only the enzymatic activities that are essential to its very existence. However, deregulated 
gene expression, combined with a high mutational load, generates aberrantly expressed, 
misfolded proteins. Removal of aberrant products is achieved by degradation through 
multifunctional complexes such as the proteasome, which is a therapeutic target [142]. 
Inhibition of the proteasome [8], or epigenetic reprogramming via a deacetylase inhibitor 
[144], may lead to activation of homeostatic responses and NF-κB, and rescue a malignant 
cell from antineoplastic treatments. One such example is the induction of lysosome activity 
after inhibition of the proteasome: this is not only a trigger for lysosome-dependent 
degradation of IκB, but it can also result in rescue of the cancer cell through autophagy, 
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which enables it to survive by recycling many of its contents [145]. It is therefore important 
to target therapeutic intervention to the drug-induced metabolic pathway that rescues the 
malignant cell.
It is therefore evident that interactions between cancer and stroma can include exchange of 
microvesicles, exosomes, cytokines, growth factors, and metabolites. Drastic changes in 
proteins that function as critical nodes of the NF-κB network disrupt key feedback responses 
and essential mechanisms of oscillation for NF-κB activity. Neoplastic tissue is 
characterized by particularly high levels of certain metabolites and enzymatic activities, with 
resultant breakdown of regulatory mechanisms and establishment of abnormal ratios 
between critical rheostat molecules located in organelles and on chromatin. As metabolites 
and homeostatic mechanisms depend heavily on the host tissue, no animal model or current 
in vitro system can be viewed as faithful reproduction of a cancer host: key challenge in the 
field is to develop in vitro models that will enable characterizing changes of inflammatory 
mediators in specific states of cancer development.
Conclusions and outlook
It is becoming increasingly clear that many aspects of inflammation influence the course of 
malignant disease decisively. NF-κB driven inflammatory gene expression programs are 
known mediators of cancer-related mortality [146]. This article presents a few mechanisms 
that have drastic effects on the cancer cell microenvironment, when their impact on NF-κB 
activity is altered. The next decade is expected to define cancer in terms of an aberrant 
function of the NF-κB network. Inflammatory signal pathways and NF-κB activation in 
malignant tumors neither follow a normal pattern of function nor respond to modulators in a 
readily expected fashion [74,144]; their secreted targets, nonetheless, can be readily 
identified. Compounds that inhibit the activation of selected subsets of NF-κB-dependent 
genes are increasingly being assayed in preclinical studies [29]; metabolic intervention, 
however, is closer to clinical application [14]. NF-κB driven signals, through their 
downstream targets convey the capacity for rapid responses and systemic amplification to 
inflammation, being capable to change cellular function, especially in relation to host tissue. 
Disruption of NF-κB feedback regulation explains is why this factor from a mechanism of 
tumor control gains the potential to transform the clinical course of the disease, since tumors 
that involve diverse oncogenes evolve into cancer after dysregulation of NF-κB. There are 
multiple control mechanisms with partly overlapping effects on NF-κB activity. As a 
paradigm, regulation of NF-κB by transcription factors STAT3, GR, and p53, which 
mediate effects of metabolism and stress, does not function as in normal cells. Loss of 
feedback for those mechanisms changes key properties of a neoplastic cell and alters tissue 
steady state. The result is an aberrant interaction with the host tissue and the immune 
system, with impact on discrete cancer cell subpopulations and the resulting 
microenvironment. Importantly, dysregulation of NF-κB activity affects oncogenesis, 
because it enables a tumor cell to combine key properties of stem cells with essential 
adaptation features of a differentiated cell. Characterization of the modules that control NF-
κB activity points at designing treatment according to the biological state of host tissue. In 
the near future, selective inhibition of signal pathways interacting with NF-κB could prove 
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effective in combination with cell-targeted agents, and contribute significantly to 
personalized cancer treatment.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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*Highlights (for review)
- During inflammation, a sequential activation of different cell types takes place, 
induced by cytokines, chemokines, and adhesion factors. Malignant cells can express 
combinations of cytokines, chemokines, and adhesion factors from different stages 
of the inflammatory cascade.
- Dysregulation of NF-κB activity affects oncogenesis, because it enables a tumor 
cell to combine selected properties of stem cells with tissue adaptation features of a 
differentiated cell. This dysregulation influences several gene cohorts in subsets of 
cancer cells; however, it has far-ranging effects on the entire organism through 
disruption of essential mediators of homeostasis.
- Regulation of NF-κB by transcription factors signal transducer and activator of 
transcription-3 (STAT3), glucocorticoid receptor (GR), and p53 protein, which 
mediate effects of metabolism and stress, does not function in cancer cells as in 
normal cells. The result is an aberrant interaction with the host tissue and the 
immune system, with impact on discrete cancer cell subpopulations and their 
microenvironment.
Vlahopoulos et al. Page 26
Cytokine Growth Factor Rev. Author manuscript; available in PMC 2016 August 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig.1. 
A: depiction of the primary structure of RelA. A few representative examples of 
posttranslational modifications are shown. A schematic outline of relevant pathways is given 
in the Kyoto Encyclopedia of Genes and Genomes resource at http://www.kegg.jp/pathway/
hsa04064
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Fig. 2. 
A: During inflammation, a sequential activation of different types of leukocytes takes place, 
induced by cytokines, chemokines, and adhesion factors. Malignant cells express subsets of 
genes that are normally induced in cell subtypes that are essential for survival of the 
organism.
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Fig.3. 
A: A simplified, schematic depiction of three representative signal pathways with proven 
potential to interact with intracellular signal relay mechanisms regulated by NF-κB. B: 
STAT3 and NF-κB induce unique combinations of gene cohorts with an activity profile that 
can distinguish subgroups of malignant cells. C: A model drug (red arrow) that inhibits a 
tyrosine kinase involved in NF-κB activation (here Bruton tyrosine kinase “BTK”), will fail 
to work when NF-κB is constitutively active (blue arrow), and can thereby saturate 
regulatory sequences (promoters and enhancers) of its oncogenic targets.
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Fig. 4. 
Immune response is impaired in the vicinity of cells secreting mediators as IL-10, or 
prostaglandin E2, while other tissue sites, upon a local increase in e.g., IL-12, or TNFα have 
increased risk of cellular infiltrations and organ damage.
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Fig. 5. 
Chromatin immunoprecipitation data of the ENCODE project, for binding of transcription 
factors NF-κB RelA, STAT3, and c-Myc. A: on human chromosome 8q24.21 locus of the 
myc gene . B: On the chromosome 19q13.2, locus of the tgfb1 gene (red zone).
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Table 1
Identities of representative isoforms of the proteins referred herein, according to the National Center of 
Biotechnology Information (NCBI) and the Online Mendelian Inheritance in Man catalog (OMIM) that 
outlines the current consensus for the biological role of each entry.
Protein name NCBI (Entrez Gene ID) OMIM entry
AKT1 207 164730
AMPK 5562 602739
AR 367 313700
Bcl-2 596 151430
Bfl1 597 601056
Calpain1 / mu I 823 114220
Calpain2 / m II 824 114230
CCL2 6347 158105
CCL20 6364 601960
CCL5 6352 187011
ccnd1 (cyclin D1) 595 168461
CD11b 3684 120980
CD8 925 186910
CD44 960 107269
COX2 5743 600262
CSF3 1440 138970
CXCL1 2919 155730
CXCL1O 3627 147310
ER 2099 133430
Fascin-1 6624 602689
Foxp3 50943 300292
GATA3 2625 131320
GRα 2908 138040
Hexokinase 2 3099 601125
HIF1 3091 603348
HMG-CoA reductase 3156 142910
IFNα 3439 147660
IFNβ 3456 147640
IFNγ 3458 147570
IkBα 4792 164008
IKK1 1147 600664
IKK2 3551 603258
IL-10 3586 124092
IL-12A 3592 161560
IL-12B 3593 161561
IL-1β 3553 147720
IL-2 3558 147680
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Protein name NCBI (Entrez Gene ID) OMIM entry
IL-23A 51561 605580
IL-6 3569 147620
IL-8 3576 146930
JAK2 3717 147796
Mcl-1 4170 159552
MMP2 4313 120360
MMP9 4318 120361
Myc 4609 190080
Nanog 79923 607937
NFkB1 (p50) 4790 164011
NFkB2 4791 164012
P53 7157 191170
PFKB3 5209 605319
Proteasome subunit A1 5682 602854
Proteasome subunit C5 5705 601681
Ras (KRAS1) 3845 190070
Rb (Rb1) 5925 614041
Rel 5966 164910
RelA 5970 164014
RelB 5971 604758
Src 6714 190090
STAT3 6774 102582
Tert (telomerase) 7015 187270
TGFβ 7040 190180
TLR3 7098 603029
TNF 7124 191160
VEGF 7422 192240
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